Quincy Chu
Contact
Faculty of Medicine & Dentistry - Oncology Dept
- qschu@ualberta.ca
Overview
Area of Study / Keywords
About
I received my BSc in biochemistry at McMaster University, followed by my MD at the University of Toronto. After I finished my internal medicine and medical oncology training at the University of Western Ontario, I pursued my fellowship training in advanced novel anti-cancer therapeutics at the Institute for Drug Development, San Antonio Texas. During my fellowship, my main focuses are on early clinical and translational development on novel anti-cancer therapeutics and clinical pharmacology.Research
Phase I/II Clinical Research: From 2002 to 2005, I pursued a clinical research fellowship in the development of novel anti-cancer agents, including cytotoxic, molecular targeted and
Translational Research in Novel Anti-cancer Agents: Due to the heterogeneity of clinical and molecular characteristics of solid tumours, there is
Translational Research in Adult Soft Tissue Sarcomas: Adult soft tissue sarcoma is a class of rare and
Teaching
Aside from bedside or more accurate called clinic teaching of rotating medical students, medicine, surgery and pathology residents, medical oncology and respiratory fellows, I teach the basics on clinical trial designs for the medical oncology fellows. In addition, I coordinate the biannual Clinical Pharmacology series for the medical oncology fellows with Drs. Sawyer and Spratlin.
I am also a teaching faculty for the Faculty of Agriculture and Nutrition annually on nutritional complications from anti-cancer agents.
Featured Publications
ASCO (Oral Presentation). 2022 June; 10.1200/JCO.2022.40.16_suppl.2500
Nowak K., Formenti K., Huang J., Bigras G., Chu Q., Adam B.A., Izevbaye I.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2022 June; 148 (6):1325-1336 10.1007/s00432-022-03924-3
Murphy R.A., Darvishian M., Qi J., Chen Y., Chu Q., Vena J., Dummer T.J.B., Le N., Sweeney E., DeClercq V., Grandy S.A., Keats M.R., Cui Y., Awadalla P., Brenner D.R., Bhatti P.
Cancer Causes and Control. 2022 June; 33 (6):913-918 10.1007/s10552-022-01566-x
American Society of Hematology Ann Meeting (Poster). 2022 May; n/a
Herbst R.S., Majem M., Barlesi F., Carcereny E., Chu Q., Monnet I., Sanchez-Hernandez A., Dakhil S., Camidge D.R., Winzer L., Soo-Hoo Y., Cooper Z.A., Kumar R., Bothos J., Aggarwal C., Martinez-Marti A.
Journal of Clinical Oncology. 2022 April; 3 10.1200/JCO.22.00227
Riopel N.D., Chu Q., Walker J., Ye C.
Journal of Immunotherapy. 2022 April; 45 (4):207-209 10.1097/CJI.0000000000000409
Jogiat U.M., Chu Q.S., Nagendran J., Laing B., Hirji A., Adam B.A.
ANTICANCER RESEARCH. 2022 February; 42 (2):1157-1160 10.21873/anticanres.15580
Zhang L., Coffin J., Formenti K., Chu Q., Izevbaye I.
BMJ Open Respiratory Research. 2022 January; 9 (1) 10.1136/bmjresp-2021-001154
Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review
Khwaja R.M., Chu Q.S.C.
Current Oncology. 2022 January; 29 (2):479-489 10.3390/curroncol29020043
Cheema P.K., Banerji S.O., Blais N., Chu Q.S.C., Desmeules P., Juergens R.A., Leighl N.B., Sheffield B.S., Wheatley-Price P.F., Melosky B.L.
Current Oncology. 2021 November; 28 (6):4552-4576 10.3390/curroncol28060386
Melosky B., Cheema P., Juergens R.A., Leighl N.B., Liu G., Wheatley-Price P., Sacher A., Snow S., Tsao M.S., McLeod D., Chu Q.
Therapeutic Advances in Medical Oncology. 2021 November; 13 10.1177/17588359211056306
Rottey S., Clarke J., Aung K., Machiels J.P., Markman B., Heinhuis K.M., Millward M., Lolkema M., Patel S.P., De Souza P., Duca M., Curigliano G., Santoro A., Koyama T., Brown M., Vezina H., He C., Siu-Chung Chu Q.
CLINICAL CANCER RESEARCH. 2021 October; 28 (1):95-105 10.1158/1078-0432.CCR-21-1181
Melosky B., Wheatley-Price P., Juergens R.A., Sacher A., Leighl N.B., Tsao M.S., Cheema P., Snow S., Liu G., Card P.B., Chu Q.
Lung Cancer. 2021 October; 160 10.1016/j.lungcan.2021.06.002
Grosjean H.A.I., Dolter S., Meyers D.E., Ding P.Q., Stukalin I., Goutam S., Kong S., Chu Q., Heng D.Y.C., Bebb D.G., Morris D.G., Cheung W.Y., Pabani A.
Current Oncology. 2021 October; 28 (5):4213-4222 10.3390/curroncol28050357
ESMO (Oral Presentation). 2021 September; S1283-S1346. 10.1016/annonc/annonc741
Chu Q.S.c., Bouganim N., Fortier C., Zaknoen S., Stille J.R., Kremer J.D., Yuen E., Hui Y.H., de la Peña A., Lithio A., Smith P.S., Batist G.
Investigational New Drugs. 2021 August; 39 (4):1001-1010 10.1007/s10637-020-01049-3
Journal of Clinical Oncology . 2021 May; 10.1200/JCO.2021.39.15_suppl.2513
Journal of Clinical Oncology . 2021 May; 10.1200/JCO.2021.39.15_suppl.2582
Chu Q.S.c., Bouganim N., Fortier C., Zaknoen S., Stille J.R., Kremer J.D., Yuen E., Hui Y.H., de la Peña A., Lithio A., Smith P.S., Batist G.
Investigational New Drugs. 2021 January; 39 (4):1001-1010 10.1007/s10637-020-01049-3
3. Zhang L, Coffin J, Formenti K, Chu Q, Izevbaye I. Comparative Study of Three Assays: Target Capture Sequencing, MassARRAY and Real-Time qPCR for testing Somatic Mutations in Plasma Cell-Free Circulation Tumour DNA of Non-Small Cell Lung Cancer. AMP 2020: TT10
AMP. 2020 December;
Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial
SITC 2020. 2020 November;
Gutierrez M., Moreno V., Heinhuis K.M., Olszanski A.J., Spreafico A., Ong M., Chu Q., Carvajal R.D., Trigo J., de Olza M.O., Provencio M., de Vos F.Y., de Braud F., Leong S., Lathers D., Wang R., Ravindran P., Feng Y., Aanur P., Melero I.
Clinical Cancer Research. 2020 November; 27 (2):460-472 10.1158/1078-0432.CCR-20-1830
Melosky B., Cheema P.K., Brade A., McLeod D., Liu G., Price P.W., Jao K., Schellenberg D.D., Juergens R., Leighl N., Chu Q.
Oncologist. 2020 November; 25 (11):981-992 10.1634/theoncologist.2020-0193
Chu Q.S.C.
Journal of Thoracic Oncology. 2020 October; 15 (10):1561-1564 10.1016/j.jtho.2020.07.011
van der Meij B.S., Teleni L., Stanislaus A.E., Murphy R.A., Robinson L., Damaraju V.L., Chu Q., Sawyer M.B., Mazurak V.
Clinical Nutrition ESPEN. 2020 October; 40 10.1016/j.clnesp.2020.09.009